Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7923449 | 0.87 | KCNH2 (0.38) | KCNH2PPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL12918858 | 0.82 | KCNH2 (0.42) | KCNH2PPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL6547425 | 0.81 | KCNH2 (0.43) | KCNH2MTNR1AMTNR1B | |
| SCHEMBL5074222 | 0.78 | KCNH2 (0.44) | KCNA3KCNH2MTNR1AMTNR1BHRH3 | |
| SCHEMBL3637570 | 0.74 | KCNH2 (0.45) | KCNH2MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL11683567 | 0.72 | KCNH2 (0.44) | KCNH2MTNR1AMTNR1B | |
| SCHEMBL7388573 | 0.70 | TDP1 (0.45) | KCNA3HRH3 | |
| SCHEMBL3488296 | 0.69 | TSHR (0.56) | KCNA3HRH3 | |
| SCHEMBL31018369 | 0.69 | L3MBTL1 (0.51) | KCNA3HRH3ADRB2ADRB1 | |
| SCHEMBL4970515 | 0.69 | KCNH2 (0.50) | KCNH2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6174898-B1 | TREATING FILARIAE IN LYMPHATIC SYSTEM BY ADMINISTERING N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS IN WHICH A SUBSTITUTED ALKYL CHAIN FORMS PART OF N-SUBSTITUENT AND SALTS | NOVO NORDISK A/S (DK) | 2001-01-16 | — | — | US | disclosed |
| EP-0858339-A1 | A METHOD OF TREATING FILARIAE | NOVO NORDISK A/S (DK) | 1998-08-19 | — | — | EP | disclosed |
| EP-0502031-B1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION | NOVO NORDISK AS (DK) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997017073-A1 | A METHOD OF TREATING FILARIAE | NOVO NORDISK A/S (DK) | 1997-05-15 | — | — | WO | disclosed |
| US-5198451-A | Treatment of epilepsy, inhibitors of gamma-aminobutyric acid uptake from synaptic cleft | NOVO NORDISK A/S (DK) | 1993-03-30 | — | — | US | disclosed |
| EP-0502031-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION. | NOVO NORDISK AS (DK) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991007389-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION | NOVO NORDISK A/S (DK) | 1991-05-30 | — | — | WO | disclosed |